....who would be the better candidate to reign in the FDA

New Post Public Reply Private Reply Replies (0) Message Board
Bhawks Honeycomb777 #18508
Quote:
....who would be the better candidate to reign in the FDA and actually help to LOWER healthcare costs ?


Ok, fair questions. Here are Clinton's proposals. It appears that they directly address your concerns. You'll notice a proposal to fully find FDA's Office of Generic Drugs to clear out its generic drug approval backlog.

You didn't know about that, did you? That's OK, we're all learning more about what each candidate is proposing, or not proposing.

Who do you think is responsible for the funding shortfall? I'll bet it is the same Party that won't pass an Infrastructure Bill.

Same party that wants tax cuts to further 'starve the beast', forgetting that the 'beast' IS necessary to fund the building of things and for the freeing up of backlogs.

Some times 'empowering' is more important than 'reigning in'. Not always, but certainly...some times.

Make you own judgments and note the absence of a Trump proposal to address your concerns.

Also, stand by to watch conservatives who post here lose their sh*t and holler OPINiONS'


Quote:
Hillary Clinton taking on drug industry

She is unveiling a plan to drive down the cost of prescriptions.


Clinton would also attempt to spur more competition and lower prices in the drug market by a set of regulatory reforms. For instance, she wants to fully fund the FDA's Office of Generic Drugs to clear out its generic drug approval backlog.

She also proposes lowering the exclusivity period for biologic drugs from 12 to seven years.
Clinton also wants to let Americans import drugs for personal use from nations with safety standards as rigorous as those in the U.S.

Additionally, Clinton proposes cracking down on direct-to-consumer advertising. Ads for prescription drugs "can include confusing, misleading or incomplete information or exaggerated claims if not regulated effectively," her memo notes. She would eliminate corporate write-offs for direct-to-consumer advertising and establish required FDA pre-clearance for such ads.

http://www.cbsnews.com/news/hillary-clinton-r...rug-costs/

By Brett Norman

09/22/15 12:01 AM EDT

Read more: http://www.politico.com/story/2015/09/hillary...z4IaUanKbM


Like most Democrats, including Sanders, Clinton calls for empowering Medicare to leverage its massive negotiating power to lower prices for seniors. That's an idea that's been around since the Medicare drug law passed early in the George W. Bush administration, but the GOP has consistently opposed it.

Clinton and Sanders would let Americans re-import drugs from other countries, where they are often sold at half the price. And they would outlaw so-called pay-for-delay settlements in patent litigation in which brand name companies pay their generic competitors to hold off on marketing a cheaper copycat drug.

Clinton would require deeper rebates on drugs for low-income people on the Medicare program — the same provided to those on Medicaid. That's the source of the estimated $100 billion in savings.

Clinton’s plan includes some less familiar proposals as well, which were aired last week in a policy paper by the liberal Center for American Progress. Those include requiring companies that benefit from federal spending on basic research, such as through NIH, to spend a certain amount on research and development.

That's fashioned after an Obamacare requirement that insurers spend a fixed percentage of the premiums they collect on medical care, or else pay rebates to consumers.

The think tank last week also recommended giving an independent organization the authority to assess how a new drug compares to existing treatments, and recommend a price range to help insurers negotiate. Clinton is backing a similar proposal.

Read more: http://www.politico.com/story/2015/09/hillary...z4IaUFtiGh
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 1

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Combining Forces: Waters Corporation and BD to Lead Diagnostics

Updated Category News Views 331

Exciting Merger in the Life Sciences Sector In a significant move for the life sciences industry, Waters Corporation (NYSE: WAT) has officially announced its plans to merge with BD (Becton, Dickinson and Company) (NYSE: BDX). This merger aims to create a leading entity in the fields of regulated and high-volume testing. The combination is expected to harness the strengths...

Continue Reading
Citius Oncology Strengthens LYMPHIR Launch with New Partnership

Updated Category News Views 109

Citius Oncology Reinforces Distribution for LYMPHIR Citius Oncology, Inc. (Nasdaq: CTOR), a leading company in oncology therapeutics, has taken a significant step by partnering with Cencora, a global provider of pharmaceutical solutions. The newly signed distribution services agreement is aimed at enhancing commercial infrastructure and ensuring the successful launch of...

Continue Reading
Exploring Growth in Low-Code Development Platforms

Updated Category News Views 242

Surging Growth in Low-Code Development Platforms The demand for low-code development platforms is on the rise, with projected growth from USD 26.30 billion in 2025 up to USD 67.12 billion by 2030, at an impressive CAGR of 20.61%. This surge is primarily fueled by organizations adopting hybrid and multi-cloud strategies, making low-code tools essential for modernizing...

Continue Reading
Foresee Pharmaceuticals Unveils Promising Results for Linvemastat

Updated Category News Views 58

Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has...

Continue Reading
Unlocking Spring’s Real Estate Potential with Mistoria Group

Updated Category News Views 302

Why May is the Optimal Time for Real Estate Transactions As the weather warms and spring settles in, the real estate market bursts with activity. Leading property experts suggest that May is the prime month to either buy or sell a home. Mish Liyanage, the CEO of Mistoria Group, emphasizes that emerging market trends provide compelling reasons for homeowners and potential...

Continue Reading